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Abstract
Background: In the central nervous system, HIV replication can occur relatively independent of systemic
infection, and intrathecal replication of HIV-1 has been observed in patients with HIV-related and opportunistic
neurological diseases. The clinical usefulness of HIV-1 RNA detection in the cerebrospinal fluid (CSF) of patients
with opportunistic neurological diseases, or the effect of opportunistic diseases on CSF HIV levels in patients
under HAART has not been well defined. We quantified CSF and plasma viral load in HIV-infected patients with
and without different active opportunistic neurological diseases, determined the characteristics that led to a
higher detection rate of HIV RNA in CSF, and compared these two compartments.
Methods: A prospective study was conducted on 90 HIV-infected patients submitted to lumbar puncture as part
of a work-up for suspected neurological disease. Seventy-one patients had active neurological diseases while the
remaining 19 did not.
Results: HIV-1 RNA was quantified in 90 CSF and 70 plasma samples. The HIV-1 RNA detection rate in CSF was
higher in patients with neurological diseases, in those with a CD4 count lower than 200 cells/mm3, and in those
not receiving antiretroviral therapy, as well as in patients with detectable plasma HIV-1 RNA. Median viral load
was lower in CSF than in plasma in the total population, in patients without neurological diseases, and in patients
with toxoplasmic encephalitis, while no significant difference between the two compartments was observed for
patients with cryptococcal meningitis and HIV-associated dementia. CSF viral load was lower in patients with
cryptococcal meningitis and neurotoxoplasmosis under HAART than in those not receiving HAART.
Conclusion: Detection of HIV-1 RNA in CSF was more frequent in patients with neurological disease, a CD4
count lower than 200 cells/mm3 and detectable plasma HIV-1. Median HIV-1 RNA levels were generally lower in
CSF than in plasma but some patients showed higher CSF levels, and no difference between these two
compartments was observed in patients with cryptococcal meningitis and HIV-associated dementia, suggesting the
presence of intrathecal viral replication in these patients. HAART played a role in the control of CSF HIV levels
even in patients with cryptococcal meningitis and neurotoxoplasmosis in whom viral replication is potentially
higher.
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Background
The assessment of plasma viral load has led to revolution-
ary advances in the understanding of viral dynamics in the
HIV-infected organism and has become one of the most
important tools for monitoring the response to antiretro-
viral (ARV) therapy [1-4]. Highly active antiretroviral ther-
apy (HAART) has brought a real chance of effectively
controlling the infection, with high suppression of plasma
viral load and improvement of the cellular immune
response, thus reducing mortality and the incidence of
new opportunistic infections and HIV-associated demen-
tia (HIV-D) [5-11]. However, opportunistic neurological
diseases continue to occur, especially in developing coun-
tries. In Brazil, despite a public health system that pro-
vides ARV drugs free of charge, this disease continues to
occur due to irregular immunovirological monitoring and
late diagnosis of the infection [12].
Evidence indicates that in different compartments of the
body such as the central nervous system, HIV replication
can occur relatively independent of systemic infection
[13-18], and intrathecal replication of HIV-1 has been
observed in patients with HIV-related and opportunistic
neurological diseases. In contrast to plasma viral load, the
usefulness and predictive value of the analysis of cerebro-
spinal fluid (CSF) viral load are less clear [19,20].
The clinical usefulness of HIV-1 RNA detection in the CSF
of patients with opportunistic neurological diseases, or
the effect of opportunistic diseases on CSF HIV levels in
patients under HAART has not been well defined. Many
studies regarding CSF viral load have been conducted in
developed countries on patients with HIV-related neuro-
logical disease; however, few studies have been carried out
in developing countries and on patients with opportunis-
tic disease.
The objectives of the present study were to compare HIV
RNA levels in CSF and plasma of HIV-infected patients
with toxoplasmic encephalitis, cryptococcal meningitis,
HIV-D and without active neurological diseases, as well as
to determine the characteristics that led to a higher detec-
tion rate of HIV RNA in CSF and the influence of HAART
on CSF viral load.
Methods
We prospectively evaluated 90 HIV-infected patients who
were submitted to lumbar puncture between May 2002
and May 2003 as part of the work-up for a suspicion of
neurological disease at a public AIDS Reference Hospital
(Eduardo Menezes Hospital, FHEMIG), Belo Horizonte,
Brazil. The study was approved by the Research Ethics
Committee of the institution and written informed con-
sent was obtained from all participants.
Data collected from each patient included gender, age,
CD4+ lymphocyte count, use of ARV therapy, duration of
ARV therapy, and presence and type of neurological dis-
ease.
Neurological diseases were diagnosed based on the fol-
lowing criteria: criteria of the Working Group of the Amer-
ican Academy of Neurology Task Force [21] for the
diagnosis of HIV-D and vacuolar myelopathy, a suggestive
skull computed tomography scan and a clinical and tom-
ographic image response to specific drug treatment for the
diagnosis of toxoplasmosis, and a positive India ink
result, a specific cryptococcal antigen test or positive CSF
culture for the diagnosis of cryptococcal meningitis.
Tuberculous meningitis was diagnosed based on clinical-
neurological signs of lymphocytic meningitis and the
presence of alcohol-acid resistant bacilli or a positive CSF
culture. Stereotactic biopsies were obtained for the diag-
nosis of progressive multifocal leukoencephalopathy
(PML) and bacterial abscess. An undetermined diagnosis
was considered when the patients showed neurological
syndromes characterized by meningitis, encephalitis or
expansive intracranial lesions and when no etiology could
be established after work-up.
CSF samples from all 90 patients were submitted to the
quantification of HIV-1 RNA and the virus was also quan-
tified in plasma in 70 of them. Twenty patients didn't
have a plasma sample collected or samples were collected
48 hours after the CSF samples, so they were excluded
from the analysis.
CSF and plasma samples were collected within an interval
of 48 hours between each other and stored at -70°C until
the time of processing within a maximum period of 6
months. HIV-1 RNA was quantified by NASBA using 1.0
ml centrifuged plasma and 0.1 ml not centrifuged CSF
according to manufacturer instructions (Nuclisens HIV-1
QT, Organon TeKniKa, Boxtel, Netherlands), with a sensi-
tivity of 80 copies/ml (1.90 log10 copies/ml). None of the
CSF samples contained more than 10 red cells/mm3.
Statistical analysis
Individual associations of the variables CD4 T lym-
phocyte count, use of ARV therapy, presence of neurolog-
ical disease and detectable plasma HIV-1 RNA with the
detection of HIV-1 RNA in CSF were determined by the
chi-square test. Multivariate logistic regression analysis
was used to evaluate the overall effect of these four varia-
bles. The nonparametric Wilcoxon test was used for com-
parison of CSF and plasma viral load. The nonparametric
Mann-Whitney test was applied to the comparison of CSF
viral load in patients with and without ARV therapy. The
level of significance was set at 5% for all tests.BMC Infectious Diseases 2007, 7:147 http://www.biomedcentral.com/1471-2334/7/147
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A log10 transformation was performed on all HIV-1 RNA
concentration values (copies per milliliter). For patients
with undetectable HIV-1 RNA, a log-scale value of 0 was
assigned to avoid the problem of expressing zero logarith-
mically. All statistical analyses were performed with the
SPSS 8.0 program (SPSS Inc.).
Results
Characteristics of the population
Table 1 summarizes the clinical and laboratory character-
istics of the 90 patients. The median CD4+ T lymphocyte
count was 89 cells/mm3 and no differences in median
CD4 count were observed between patients with different
types of neurological diseases or between those undergo-
ing ARV therapy or not. Forty-nine (54.4%) of the 90
patients used ARV drugs, all in the HAART regimen.
Seventy-one (78.9%) of the 90 patients presented with
neurological diseases, while the remaining 19 patients
(21.1%) did not have active opportunistic or AIDS-related
neurological diseases and no clinical or laboratory evi-
dence of active infection was observed in these patients.
Detection rate of HIV RNA in CSF
HIV-1 RNA was detected in 62.2% of the 70 plasma sam-
ples and in 55.6% of the 90 CSF samples analyzed. The
detection rate of RNA HIV-1 in CSF was higher in patients
with neurological diseases (63.4%), in patients with a
CD4+ T cell count lower than 200 cells/mm3 (64.4%), in
patients not undergoing ARV therapy (82.5%), and in
patients with detectable plasma HIV-1 RNA (71.4%).
However, after multivariate analysis the use of ARV was
no longer significant in the detection of HIV-1 RNA in CSF
(Table 2).
Viral load in CSF and plasma of the 70 subjects
Median viral load was lower in CSF than in plasma in the
total population (p < 0.001), in patients without neuro-
logical diseases (p = 0.012), and in patients with toxoplas-
mic encephalitis (p = 0.013) (Table 3). In the patients
with toxoplasmic encephalitis, there was a difference
between CSF and plasma viral load, but just in the
patients that didn't use therapy. There weren't any differ-
ences in the patients that used therapy (Figure 1). On the
other hand, no significant difference between the two
compartments was observed in patients with cryptococcal
meningitis (p = 0.209) and HIV-D (p = 0.273) and this
occurred in patients that did or didn't use therapy (Figures
2 and 3). Concerning the patients that didn't have neuro-
logical disease, there was a difference of viral load
between compartments in just the patients that used ther-
apy (p = 0,043) (Figure 4).
In absolute values, the median plasma and CSF viral load
ratio was approximately 28:1, and this ratio was lower in
patients with neurological diseases (12 times) and higher
in patients without neurological diseases (335 times). The
lowest ratio was observed in patients with cryptococcal
meningitis (3.4 times) and HIV-D (3 times). Twelve
(17%) of the 70 patients for whom concomitant CSF and
plasma samples were available showed higher absolute
values in CSF than in plasma, with 11 of them having
opportunistic disease of the central nervous system and
HIV-D. The mean and median number of cells in CSF was
higher in these patients than in the total population.
Median CSF and plasma viral load were significantly
lower in patients with opportunistic diseases in general,
cryptococcal meningitis and neurotoxoplasmosis under
HAART. Among the 35 patients with opportunistic neuro-
logical diseases in whom HIV-1 RNA was detected in CSF,
20 received HAART (median of <1.9 log10 copies/ml) and
15 did not (median of 3.76 log10). In plasma, the median
was 2.82 log10 copies/ml for patients receiving HAART
and 4.57 log10 copies/ml for those who did not.
Discussion
Detection rate of HIV-1 RNA in CSF
In the present study, the detection rate of the virus in CSF
(56%) and plasma (62%) was lower than those reported
in other investigations. One possible explanation is that
Table 1: Characteristics of the 90 subjects studied
Mean age [years (range)] 36 (20–60)
Sex (n)
Male 65
Female 25
CD4-positive cells (cells/mm3)
Mean 149
Median 89
Range 1–405
Mean time since diagnosis [month (range)] 24 (0.5–108)
Pre-existing ARV therapy (n)
Yes 49
No 40
Mean duration of ARV therapy [month (range)] 10 (0.3–60)
Neurologically asymptomatic (n) 19
Neurologically symptomatic (n) 71
HIV-associated dementia 6
Vacuolar myelopathy 1
Opportunistic CNS infections (43)
Toxoplasmosis 19
Cryptococcal meningitis 15
Tuberculosis meningitis 3
PML 2
Associations
Cryptococcal and tuberculous 3
Cryptococcal and toxoplasmosis 1
Cryptococcal and vacuolar myelopathy 1
Other (stroke, brain abscess, neuropathy) 4
Undetermined neurological diagnosis 16
ARV, antiretroviral drug; CNS, central nervous system;
PML, progressive multifocal leukoencephalopathyBMC Infectious Diseases 2007, 7:147 http://www.biomedcentral.com/1471-2334/7/147
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54% of our patients were on HAART and 21% of the
patients did not have HIV-related or secondary neurolog-
ical diseases, with neurological diseases being known to
increase viral replication in CSF and plasma and the con-
sequent detection of the virus [22-25].
Qualitative studies using PCR have shown that HIV can be
detected in CSF at frequencies ranging from 64% [26] to
90% [27]. A variable frequency has also been reported in
other studies using quantitative detection methods
depending on patient characteristics, with frequencies
ranging from 66% [23,28,29] to 98% of CSF samples. The
latter rate was reported by Gisslen et al.[30] for patients
not undergoing ARV therapy who used a more sensitive
PCR kit with a detection limit of 20 copies per ml.
Studies regarding HIV-1 RNA detection in CSF should be
analyzed with caution. First, quantitative methods have
been shown to be less sensitive than qualitative methods
[31]. Second, some studies showing a higher detection
rate of HIV-1 RNA in CSF were performed before 1998,
when most patients were not on HAART. Third, the
groups of patients analyzed in these studies differ in terms
of clinical characteristics such as time since infection,
Table 3: Median viral load in CSF and plasma of 70 patients with and without neurological disease
Patient group Copies/ml (median)
Plasma CSF pa
Total population (n = 70)
VL (absolute values) 19,200 695
Log10 4.28 2.81 < 0.001
Neurological disease (n = 58)
VL (absolute values) 22,200 1,850
Log10 4.35 3.27 < 0.001
Without neurological disease (n = 12)
VL (absolute values) 335 1
Log10 2.45 <1.9 0.012
Neurotoxoplasmosis (16)
VL (absolute values) 27,500 3,200
Log10 4.44 3.45 0.013
Cryptococcal meningitis (n = 12)
VL (absolute values) 16.500 4.900
Log10 4.22 3.70 0.209
Undetermined diseases (n = 13)
VL (absolute values) 120,000 17,000
Log10 5.08 4.23 0.028
HIV-D (n = 6)
VL (absolute values) 2,641 910
Log10 2.82 2.89 0.273
a nonparametric Wilcoxon test; VL, viral load; HIV-D; HIV-associated dementia.
Table 2: Frequency of HIV-1 RNA detection in CSF according to the clinical and laboratory characteristics of the patients
Characteristic Presence (n) CSF HIV-1 RNA p (univariate)b p (multivariate)c OR
>80 (%)a <80 (%)
Diseased Yes (71) 63.4 36.6 < 0.001 0.0010 22.1
No (19) 26.3 73.7
CD4 <200 (17) 64.4 35.6 < 0.001 0.0021 18.7
>200 (73) 17.6 82.4
ARV use No (40) 82.5 17.5 < 0.001 NS *
Yes (49) 34.7 65.3
Plasma viral load >80 (56)a 71.4 28.6 < 0.001 0.0008 22.6
<80 (14) 14.3 85.7
aDetection limit: 80 copies/ml; bchi-square test; cmultivariate logistic regression analysis; dneurological disease; ARV, antiretroviral drug; NS, not 
significant; OR, odds ratio.BMC Infectious Diseases 2007, 7:147 http://www.biomedcentral.com/1471-2334/7/147
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Median viral load CSF and plasma in the patients with toxoplasmic encephalitis according to antiretroviral therapy Figure 1
Median viral load CSF and plasma in the patients with toxoplasmic encephalitis according to antiretroviral therapy.
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Median viral load CSF and plasma in the patients with cryptococcal meningitis according to antiretroviral therapy Figure 2
Median viral load CSF and plasma in the patients with cryptococcal meningitis according to antiretroviral therapy.
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Median viral load CSF and plasma in the patients with Dementia-HIV according to antiretroviral therapy Figure 3
Median viral load CSF and plasma in the patients with Dementia-HIV according to antiretroviral therapy.
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Median viral load CSF and plasma in the patients with no neurological disease Figure 4
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presence of HIV-related or secondary neurological dis-
ease, or absence of symptoms. Finally, in the case of quan-
titative methods, the sensitivity of the method used might
influence the detection rate of HIV-1 in CSF.
Detection of HIV-1 RNA in CSF varied according to the
characteristics of the population and was higher in
patients with a CD4 count lower than 200 cells/mm3,
patients with neurological disease, patient not using ARV
drugs, and patients with detectable plasma HIV-1 RNA,
but use of ARV therapy was no longer significant upon
multivariate analysis.
The chance of detecting HIV-1 RNA in CSF of patients
with neurological diseases was approximately 22 times
higher than in patients without neurological diseases. In
patients with a CD4 count lower than 200 cells/mm3 the
chance was almost 19 times higher when compared to
patient with a CD4 count higher than 200 cells/mm3, and
a 23 times higher chance of detecting HIV-1 RNA in CSF
was observed in patients with detectable plasma viral
load.
The unfavorable effect of neurological diseases on CSF
HIV levels has also been shown to be independent of ARV
therapy and may depend both on the increased permea-
bility of the blood-brain barrier, associated with enhanced
trafficking of infected cells and cytokines during neurolog-
ical disease, and on the increased local production of HIV-
1 despite systemic antiviral control [15]. However,
median CSF viral load was lower in patients with crypto-
coccal meningitis and neurotoxoplasmosis receiving
HAART than in those with cryptococcal meningitis and
neurotoxoplasmosis who did not use HAART, demon-
strating that HAART plays a certain role in the control of
CSF viral load in these patients with potential intrathecal
viral replication.
HIV-1 RNA levels in CSF have been shown to be corre-
lated with opportunistic neurological diseases [24,25]
and HIV-D [22], and HIV-1 RNA is more easily detected in
patients not undergoing HAART [15,32]. HAART has been
shown to be effective in reducing viral replication in both
plasma and CSF [15,33-35].
Viral load in CSF and plasma
Significant differences in median viral load between the
two compartments (plasma and CSF) were also observed
in the total population studied and in patients with and
without neurological diseases, but there was no difference
when individuals with cryptococcal meningitis and HIV-
D were considered separately and this occurred in patients
that did or didn't use therapy. The ratio between median
plasma and CSF viral load was lower in these patients,
showing that HIV-1 RNA levels increased in the two com-
partments, but the increase was more significant in CSF,
probably due to intrathecal replication of HIV-1 or to
increased passage of the virus through the blood-brain
barrier in these patients. The difference between CSF and
plasma viral load is considered to be an independent sign
of viral replication in the cerebral compartment [36,37].
In absolute values, the median viral load was 28 times
higher in plasma than in CSF, but in 12 (17%) of the 70
patients for whom concomitant CSF and plasma viral
loads were available, HIV levels were higher in CSF than
in plasma. These findings are similar to reports in the lit-
erature showing that median or mean plasma levels are
usually higher than the corresponding concentrations in
CSF, but CSF viral load can be higher in individual
patients [25,29,33,38-42]. CSF HIV-1 RNA levels are often
relatively low, approximately 1 log lower than plasma lev-
els [43]. The finding that 17% of the patients had a higher
viral load in CSF than in plasma supports the theory that
HIV levels in CSF do not merely reflect plasma HIV levels.
Conclusion
Detection of HIV-1 RNA in CSF was directly related to the
characteristics of the patients such as the presence of neu-
rological disease, a CD4 count lower than 200 cells/mm3,
and detectable plasma HIV-1 RNA. Median HIV-1 RNA
levels were generally lower in CSF than in plasma but
some patients showed higher CSF levels, and no differ-
ence between these two compartments was observed in
patients with cryptococcal meningitis and HIV-D, suggest-
ing the presence of intrathecal viral replication in these
patients. HAART played a role in the control of CSF HIV
levels even in patients with cryptococcal meningitis and
neurotoxoplasmosis in whom viral replication is poten-
tially higher.
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